KDR and renal cell carcinoma: Supportive evidence for anti-tumor activity of foretinib by inhibition of c-Met and vascular endothelial growth factor receptor 2 was obtained in models of hepatocellular carcinoma [39], renal cell carcinoma [40], and gastric cancer [41] which also underscores the importance to simultaneously target the tumor microenvironment by blocking neo-vascularization.